--- title: Diagnostic Precision Blog | cfDNA (2) description: cfDNA | A SeraCare blog focused on precision medicine and advanced clinical diagnostics (2) --- [![SeraCare](https://blog.seracare.com/hs-fs/hubfs/0.%20Logos/SeraCare/SeraCare.png?width=400&name=SeraCare.png "SeraCare")](https://www.seracare.com) - [Home](https://blog.seracare.com/ngs) - [About](https://digital.seracare.com/about-blog) - [News and Events](http://www.seracare.com/NewsEvents/NewsCenter/tabid/354/Default.aspx) - [Contact](http://www.seracare.com/Contact/tabid/366/Default.aspx) ## [Diagnostic Precision](https://blog.seracare.com/) A SeraCare blog focused on precision medicine and advanced clinical diagnostics Choose your Article Focus | [NGS](https://blog.seracare.com/ngs) | [Molecular & Serology](https://blog.seracare.com/molecular-serology-blog) ## [Precision Medicine and Clinical Labs: AACR Dinner Seminar Recap](https://blog.seracare.com/ngs/precision-medicine-and-clinical-labs-aacr-dinner-seminar-wrap-up) Category: [clinical genomics](https://blog.seracare.com/ngs/tag/clinical-genomics), [cfDNA](https://blog.seracare.com/ngs/tag/cfdna), [AACR](https://blog.seracare.com/ngs/tag/aacr) Posted by [Trevor Brown](https://blog.seracare.com/ngs/author/trevor-brown) on Apr 15, 2019 12:00:00 AM [![](https://blog.seracare.com/hubfs/Imported_Blog_Media/aacrvipdinner.jpg)](https://blog.seracare.com/ngs/precision-medicine-and-clinical-labs-aacr-dinner-seminar-wrap-up) One of the core aims of precision medicine is to provide a more tailored approach to disease diagnosis, therapy selection, and patient monitoring to improve the overall quality of life for patients with disease. Indeed, this aim has been at the heart of the high interest and study of the potential of liquid biopsies to improve patient care in earlier detection of cancer, treatment, and surveillance. [Read More](https://blog.seracare.com/ngs/precision-medicine-and-clinical-labs-aacr-dinner-seminar-wrap-up) 0 Comments [Click here to read/write comments](https://blog.seracare.com/ngs/precision-medicine-and-clinical-labs-aacr-dinner-seminar-wrap-up#comments-listing) ## [Customer Data: Use of Seraseq ctDNA Reference Samples to Validate Detection of Low Frequency Variants in a cfDNA-based NGS Lung Cancer Panel](https://blog.seracare.com/ngs/customer-data-use-of-seraseq-ctdna-reference-samples-to-validate-detection-of-low-frequency-variants-in-a-cfdna-based-ngs-lung-cancer-panel) Category: [AMP](https://blog.seracare.com/ngs/tag/amp), [SeraSeq](https://blog.seracare.com/ngs/tag/seraseq), [cfDNA](https://blog.seracare.com/ngs/tag/cfdna), [Lung Cancer](https://blog.seracare.com/ngs/tag/lung-cancer), [ctDNA](https://blog.seracare.com/ngs/tag/ctdna) Posted by [Omo Clement, PhD](https://blog.seracare.com/ngs/author/omo-clement-phd) on Feb 14, 2019 12:00:00 AM [![](https://blog.seracare.com/hubfs/Imported_Blog_Media/customer-data-table-1.jpg)](https://blog.seracare.com/ngs/customer-data-use-of-seraseq-ctdna-reference-samples-to-validate-detection-of-low-frequency-variants-in-a-cfdna-based-ngs-lung-cancer-panel) At the recently-concluded 2018 AMP Meeting, researchers at the New York Presbyterian Hospital (NYPH) and Weill Cornell Medical Center (WCMC) presented a poster1 on the validation of an Oncomine™ cell-free DNA Lung Assay using ctDNA NGS standards developed by SeraCare (Seraseq® ctDNA v2 Reference Materials),2 [Read More](https://blog.seracare.com/ngs/customer-data-use-of-seraseq-ctdna-reference-samples-to-validate-detection-of-low-frequency-variants-in-a-cfdna-based-ngs-lung-cancer-panel) 0 Comments [Click here to read/write comments](https://blog.seracare.com/ngs/customer-data-use-of-seraseq-ctdna-reference-samples-to-validate-detection-of-low-frequency-variants-in-a-cfdna-based-ngs-lung-cancer-panel#comments-listing) ## [Two Must-See Liquid Biopsy Poster Videos From AMP 2018](https://blog.seracare.com/ngs/two-must-see-liquid-biopsy-posters-from-amp-2018) Category: [AMP](https://blog.seracare.com/ngs/tag/amp), [SeraSeq](https://blog.seracare.com/ngs/tag/seraseq), [liquid biopsy](https://blog.seracare.com/ngs/tag/liquid-biopsy), [cfDNA](https://blog.seracare.com/ngs/tag/cfdna), [ctDNA](https://blog.seracare.com/ngs/tag/ctdna) Posted by [Sam Blier](https://blog.seracare.com/ngs/author/sam-blier) on Dec 7, 2018 12:00:00 AM [![](https://blog.seracare.com/hubfs/Imported_Blog_Media/Video%20Analytical%20Validation%20516x-1.jpg)](https://blog.seracare.com/ngs/two-must-see-liquid-biopsy-posters-from-amp-2018) Of the many fantastic posters presented at AMP’s Annual Meeting in San Antonio, two concerning NGS-based liquid biopsy assays stood out. Both presenters described how their organizations are working to reliably detect pathogenic variants at extremely low allele frequencies – efforts critical to the clinical adoption of NGS-based liquid biopsy assays. [Read More](https://blog.seracare.com/ngs/two-must-see-liquid-biopsy-posters-from-amp-2018) 0 Comments [Click here to read/write comments](https://blog.seracare.com/ngs/two-must-see-liquid-biopsy-posters-from-amp-2018#comments-listing) ## [Three liquid biopsy problems solved by the most patient-like ctDNA reference materials](https://blog.seracare.com/ngs/how-the-most-patient-like-ctdna-reference-materials-solve-three-problems) Category: [cfDNA](https://blog.seracare.com/ngs/tag/cfdna), [ctDNA](https://blog.seracare.com/ngs/tag/ctdna), [reference materials](https://blog.seracare.com/ngs/tag/reference-materials) Posted by [Dale Yuzuki](https://blog.seracare.com/ngs/author/dale-yuzuki) on Jul 24, 2017 12:00:00 AM [![](https://blog.seracare.com/hubfs/Imported_Blog_Media/DNA%20non-stabilizer%20form%20chart.png)](https://blog.seracare.com/ngs/how-the-most-patient-like-ctdna-reference-materials-solve-three-problems) Clinical genomics laboratories are increasingly looking to liquid biopsy cancer assays to complement their current solid tumor assays. Compared to their solid tumor assay counterparts, circulating tumor DNA (ctDNA) assays offer a different set of challenges to consider for clinical labs. One of the most important of which, is to develop a set of reagents that are appropriately validated to determine the critical performance of the assay across many parameters. The ctDNA targets of liquid biopsy assays are typically at much lower allelic frequencies and require a robust and reproducibly designed assay to consistently detect these important variants. [Read More](https://blog.seracare.com/ngs/how-the-most-patient-like-ctdna-reference-materials-solve-three-problems) 0 Comments [Click here to read/write comments](https://blog.seracare.com/ngs/how-the-most-patient-like-ctdna-reference-materials-solve-three-problems#comments-listing) [Previous](https://blog.seracare.com/ngs/tag/cfdna/page/1) [All posts](https://blog.seracare.com/ngs/all) ### Subscribe Here!   ### Posts by Tag - [NGS (64)](https://blog.seracare.com/ngs/tag/ngs) - [reference materials (37)](https://blog.seracare.com/ngs/tag/reference-materials) - [clinical genomics (30)](https://blog.seracare.com/ngs/tag/clinical-genomics) - [ctDNA (29)](https://blog.seracare.com/ngs/tag/ctdna) - [cancer (24)](https://blog.seracare.com/ngs/tag/cancer) - [SeraSeq (16)](https://blog.seracare.com/ngs/tag/seraseq) - [cfDNA (14)](https://blog.seracare.com/ngs/tag/cfdna) - [NIPT (12)](https://blog.seracare.com/ngs/tag/nipt) - [RNA fusion (11)](https://blog.seracare.com/ngs/tag/rna-fusion) - [AACR (10)](https://blog.seracare.com/ngs/tag/aacr) - [AMP (10)](https://blog.seracare.com/ngs/tag/amp) - [liquid biopsy (10)](https://blog.seracare.com/ngs/tag/liquid-biopsy) - [FDA (7)](https://blog.seracare.com/ngs/tag/fda) - [ccfDNA (7)](https://blog.seracare.com/ngs/tag/ccfdna) - [LDT (6)](https://blog.seracare.com/ngs/tag/ldt) - [Assay Development (5)](https://blog.seracare.com/ngs/tag/assay-development) - [Reproductive Health (5)](https://blog.seracare.com/ngs/tag/reproductive-health) - [Accuplex (4)](https://blog.seracare.com/ngs/tag/accuplex) - [NTRK (4)](https://blog.seracare.com/ngs/tag/ntrk) - [Non-invasive Prenatal Testing (4)](https://blog.seracare.com/ngs/tag/non-invasive-prenatal-testing) - [QC Challenges (4)](https://blog.seracare.com/ngs/tag/qc-challenges) - [qc management (4)](https://blog.seracare.com/ngs/tag/qc-management) - [Lung Cancer (3)](https://blog.seracare.com/ngs/tag/lung-cancer) - [MRD (3)](https://blog.seracare.com/ngs/tag/mrd) - [New Reference Material (3)](https://blog.seracare.com/ngs/tag/new-reference-material) - [#Quality (2)](https://blog.seracare.com/ngs/tag/quality) - [EGFR (2)](https://blog.seracare.com/ngs/tag/egfr) - [Inherited Disease (2)](https://blog.seracare.com/ngs/tag/inherited-disease) - [Methylated DNA (2)](https://blog.seracare.com/ngs/tag/methylated-dna) - [Minimal Residual Disease (2)](https://blog.seracare.com/ngs/tag/minimal-residual-disease) - [Molecular Pathology (2)](https://blog.seracare.com/ngs/tag/molecular-pathology) - [PGT (2)](https://blog.seracare.com/ngs/tag/pgt) - [QC Management Software (2)](https://blog.seracare.com/ngs/tag/qc-management-software) - [TMB (2)](https://blog.seracare.com/ngs/tag/tmb) - [Women's health (2)](https://blog.seracare.com/ngs/tag/womens-health) - [myeloid cancer reference materials (2)](https://blog.seracare.com/ngs/tag/myeloid-cancer-reference-materials) - [ngs validation (2)](https://blog.seracare.com/ngs/tag/ngs-validation) - [trisomy (2)](https://blog.seracare.com/ngs/tag/trisomy) - [zika virus (2)](https://blog.seracare.com/ngs/tag/zika-virus) - [BioFidelity (1)](https://blog.seracare.com/ngs/tag/biofidelity) - [Breast Cancer (1)](https://blog.seracare.com/ngs/tag/breast-cancer) - [COVID-19 (1)](https://blog.seracare.com/ngs/tag/covid-19) - [Customer Testimonial (1)](https://blog.seracare.com/ngs/tag/customer-testimonial) - [Genomic Testing (1)](https://blog.seracare.com/ngs/tag/genomic-testing) - [HIV (1)](https://blog.seracare.com/ngs/tag/hiv) - [Immuno-Oncology (1)](https://blog.seracare.com/ngs/tag/immuno-oncology) - [PGS (1)](https://blog.seracare.com/ngs/tag/pgs) - [PGT-A (1)](https://blog.seracare.com/ngs/tag/pgt-a) - [Preimplantation genetic testing (1)](https://blog.seracare.com/ngs/tag/preimplantation-genetic-testing) - [QC Reporting (1)](https://blog.seracare.com/ngs/tag/qc-reporting) - [QC data management (1)](https://blog.seracare.com/ngs/tag/qc-data-management) - [Quality Management Systems (1)](https://blog.seracare.com/ngs/tag/quality-management-systems) - [SARS-CoV-2 (1)](https://blog.seracare.com/ngs/tag/sars-cov-2) - [bioinformatics (1)](https://blog.seracare.com/ngs/tag/bioinformatics) - [laboratory training (1)](https://blog.seracare.com/ngs/tag/laboratory-training) - [listeria (1)](https://blog.seracare.com/ngs/tag/listeria) - [methylated (1)](https://blog.seracare.com/ngs/tag/methylated) See all ### Recent Posts **About SeraCare** With over 30 years of experience as a leading partner to global in vitro diagnostics manufacturers and clinical testing laboratories, SeraCare’s clinical genomics technologies enable the promise of precision medicine by helping scientists and clinicians build and implement better clinical genomics assays. [Learn More](http://www.seracare.com/Company/WhoWeAre/tabid/335/Default.aspx)    - - - [Privacy Policy](http://www.seracare.com/PrivacyPolicy/tabid/211/Default.aspx)  |  [Legal Statement ](http://www.seracare.com/LegalStatement/tabid/212/Default.aspx) **Learn More** [Home](http://seracare.com/)  [About Us](http://seracare.com/Company/WhoWeAre/tabid/335/Default.aspx) [News and Events](http://www.seracare.com/NewsEvents/NewsCenter/tabid/354/Default.aspx)  [Blog](https://blog.seracare.com/)  [Contact](http://seracare.com/Contact/tabid/366/Default.aspx)  ![LGC+Marine-logo-FINAL-teal](https://blog.seracare.com/hs-fs/hubfs/1.%20Logos/LGC+Marine-logo-FINAL-teal.png?width=150&name=LGC+Marine-logo-FINAL-teal.png) 37 Birch Street Milford, MA 01757 [508-244-6400](tel:508-244-6400) l [800-676-1881](tel:800-676-1881) [info@seracare.com](mailto:info@seracare.com) ©2017 SeraCare Life Sciences, Inc. - [About SeraCare](http://www.seracare.com/Company/WhoWeAre/tabid/335/Default.aspx) - [Learn More](http://seracare.com/) - 37 Birch Street Milford, MA 01757 - Google Maps - 508-244-6400 - 508-634-3334 Fax - - - ![logo](https://blog.seracare.com/hubfs/logo.png "logo") 37 Birch Street Milford, MA 01757 508-244-6400 508-634-3334 Fax #### Products #### SeraCare #### Support & Resources - NGS & Digital PCR Tools - Controls & Reference Materials - Validation & Qualification Materials - Plasma & Serum Diluents & Derivatives - Cell Culture Reagents - KPL Antibodies & Conjugates - KPL Immunoassay Reagents & Kits - About Us - Careers - Press Releases - News Articles - Quality Systems - Terms & Conditions - Privacy Policy & Legal Statement - Register for an Account - Contact Us - Sign In - Resource Library - FAQs - Scientific Posters - White Papers - Videos